241 related articles for article (PubMed ID: 26956429)
1. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
Yeo SY; Itahana Y; Guo AK; Han R; Iwamoto K; Nguyen HT; Bao Y; Kleiber K; Wu YJ; Bay BH; Voorhoeve M; Itahana K
Elife; 2016 Mar; 5():e07101. PubMed ID: 26956429
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer.
Zhang S; Yao HF; Li H; Su T; Jiang SH; Wang H; Zhang ZG; Dong FY; Yang Q; Yang XM
Cell Oncol (Dordr); 2023 Oct; 46(5):1473-1492. PubMed ID: 37246171
[TBL] [Abstract][Full Text] [Related]
4. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.
Miyoshi N; Ishii H; Mimori K; Tanaka F; Hitora T; Tei M; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2010 Apr; 17(4):967-72. PubMed ID: 20033322
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
Erdem M; Erdem S; Sanli O; Sak H; Kilicaslan I; Sahin F; Telci D
Urol Oncol; 2014 Jan; 32(1):25.e13-20. PubMed ID: 23499501
[TBL] [Abstract][Full Text] [Related]
6. Organization and chromosomal mapping of mouse Gh/tissue transglutaminase gene (Tgm2).
Nanda N; Iismaa SE; Copeland NG; Gilbert DJ; Jenkins N; Graham RM; Sutrave P
Arch Biochem Biophys; 1999 Jun; 366(1):151-6. PubMed ID: 10334875
[TBL] [Abstract][Full Text] [Related]
7. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.
Malkomes P; Lunger I; Oppermann E; Lorenz J; Faqar-Uz-Zaman SF; Han J; Bothur S; Ziegler P; Bankov K; Wild P; Bechstein WO; Rieger MA
Cancer Gene Ther; 2023 Oct; 30(10):1346-1354. PubMed ID: 37443286
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.
Huang YC; Wei KC; Chang CN; Chen PY; Hsu PW; Chen CP; Lu CS; Wang HL; Gutmann DH; Yeh TH
PLoS One; 2014; 9(9):e108228. PubMed ID: 25247996
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
11. Fyn Phosphorylates Transglutaminase 2 (Tgm2) and Modulates Autophagy and p53 Expression in the Development of Diabetic Kidney Disease.
Uehara R; Yamada E; Okada S; Bastie CC; Maeshima A; Ikeuchi H; Horiguchi K; Yamada M
Cells; 2023 Apr; 12(8):. PubMed ID: 37190106
[TBL] [Abstract][Full Text] [Related]
12. Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer.
Lei Z; Chai N; Tian M; Zhang Y; Wang G; Liu J; Tian Z; Yi X; Chen D; Li X; Yu P; Hu H; Xu B; Jian C; Bian Z; Guo H; Wang J; Peng S; Nie Y; Huang N; Hu S; Wu K
Cell Death Dis; 2018 May; 9(6):579. PubMed ID: 29785022
[TBL] [Abstract][Full Text] [Related]
13. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
14. Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network.
Zhang H; McCarty N
Autophagy; 2017 Mar; 13(3):627-628. PubMed ID: 28056186
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes.
Hallstrand TS; Wurfel MM; Lai Y; Ni Z; Gelb MH; Altemeier WA; Beyer RP; Aitken ML; Henderson WR
PLoS One; 2010 Jan; 5(1):e8583. PubMed ID: 20052409
[TBL] [Abstract][Full Text] [Related]
16. Contribution of autophagic cell death to p53-dependent cell death in human glioblastoma cell line SF126.
Sakamoto Y; Kato S; Takahashi M; Okada Y; Yasuda K; Watanabe G; Imai H; Sato A; Ishioka C
Cancer Sci; 2011 Apr; 102(4):799-807. PubMed ID: 21214676
[TBL] [Abstract][Full Text] [Related]
17. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress.
Matlung HL; Neele AE; Groen HC; van Gaalen K; Tuna BG; van Weert A; de Vos J; Wentzel JJ; Hoogenboezem M; van Buul JD; VanBavel E; Bakker EN
Atherosclerosis; 2012 Oct; 224(2):355-62. PubMed ID: 22921425
[TBL] [Abstract][Full Text] [Related]
19. TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy.
Hu W; Chen S; Thorne RF; Wu M
Adv Exp Med Biol; 2019; 1206():127-149. PubMed ID: 31776983
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
